Janice Schwartz: Effect of Aging on Human Pharmacology
Janice B. Schwartz, MD , is a recognized leader in the area of cardiovascular aging, drug metabolism, and in the effects of gender on drug metabolism and responses. She graduated from Tulane Medical School, is a board-certified internist, cardiologist with significant experience in clinical pharmacology and geriatric medicine. She has been on the faculty of Stanford Medical School, Baylor College of Medicine, UCSF Schools of Medicine, Nursing, and Pharmacy, and was Professor of Medicine and Molecular Pharmacology and Chief of Clinical Pharmacology and Geriatric Medicine at Northwestern University Medical School until 2000 when she returned to the San Francisco Bay area.
She is currently Clinical Professor of Medicine and Bioengineering and Therapeutic Sciences at the University of California, San Francisco, and Director of Research at the Jewish Home, San Francisco. She has been funded by the National Institute on Aging since 1985 to elucidate the changes with aging that determine responses to therapeutic medications. Her research has involved both basic laboratory research and clinical research and she is the author of over 100 publications including scientific articles, reviews, and book chapters. She has been named one of the Best Doctors in the U.S. (geriatric medicine) and belongs to numerous professional societies including the American College of Cardiology, American Geriatrics Society, American Heart Association, and American Society for Clinical Pharmacology and Therapeutics and is a past President of the Society for Geriatric Cardiology.. She has served on the Research, Educational, and Program committees of these organizations, as Associate Editor of the Journal of the American Geriatrics Society, on the USP Expert Panel on Geriatrics; and, numerous Review Panels for the NIH and currently is a member of the Aging Systems and Geriatrics Study Section, Center for Scientific Review. Her current work focuses on improving medication use in the very oldest people and in patient groups receiving polypharmacy, as well as the translation of new therapies into clinical use to benefit the very oldest and frailest patients.